Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2018 / Cilt: 28 - Sayı: 1

Blockade of the checkpoint as new target of the immunotherapy in the treatment of cancer

Kanser tedavisinde immünoterapinin yeni hedefi olarak kontrol noktası blokajı

Pages
7–11
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper we will brieflyreview potential position of anti-PD-1, and anti-PD-L1 as novel, and very populartreatment approaches in cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In the treatment of cancer, immunotherapy is applied to retrieve more precisely targeted activities from the components of immune systems via development of treatments mimicking immune system.
📊
Key Findings & Data:To this end investigators in the field of oncologyhave conducted many studies concerning immunotherapy.
💡
Conclusion & Impact:In this paper we will brieflyreview potential position of anti-PD-1, and anti-PD-L1 as novel, and very populartreatment approaches in cancer.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In the treatment of cancer, immunotherapy is applied to retrieve more precisely targeted activities from the components of immune systems via development of treatments mimicking immune system. To this end investigators in the field of oncologyhave conducted many studies concerning immunotherapy. Cancer cells lead a relatively more independent, and uncontrolled life with their ability to evade from immunesystem when compared with normal cells. Blockade of the checkpoint has opened theway for a new targeted oncological treatment modalities . In this paper we will brieflyreview potential position of anti-PD-1, and anti-PD-L1 as novel, and very populartreatment approaches in cancer.

Özet

Kanser tedavisinde, immünoterapi, bağışıklık sistemini taklit eden tedavilerin geliştirilmesi yoluyla bağışıklık sistemi elemanlarından daha kesin hedefleri olan aktivite elde etmek için uygulanır. Bu nedenle kanser araştırmacıları tarafından son yıllarda, immunoterapi konusunda çok sayıda çalışma yapılmıştır. Kanser hücreleri, immün sistemden kaçabilme yeteneği ile normal hücrelerden daha bağımsız ve kontrolsüz bir yaşam sürer. Kontrol noktası blokajı kanser tedavisinde yeni bir hedefe yönelik tedavinin önünü açmıştır. Bu makalede, kanserde yeni ve çok popüler olan bir yaklaşım modalitesi olarak anti-PD-1 ve anti-PD-L1 gibi ajanların bugünkü ve gelecekteki olası durumlarını kısaca gözden geçireceğiz.

🔖

Cite This Article

ELİYATKIN, N. Ö., YAŞİN, B. (2022). Blockade of the checkpoint as new target of the immunotherapy in the treatment of cancer. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 28 - Sayı: 1, 7–11. https://ajindex.com/articles/558126

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800. https://doi.org/10.1038/nm730
  2. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-34. https://doi.org/10.1084/jem.192.7.1027
  3. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101(49):17174-9. https://doi.org/10.1073/pnas.0406351101
  4. Liu JZ, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-gamma and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007;110(1):296-304. https://doi.org/10.1182/blood-2006-10-051482
  5. Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clinical Cancer Research. 2013;19(13):3462-73. https://doi.org/10.1158/1078-0432.CCR-13-0855
  6. Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata. Cancer. 2007;109(8):1499-1505. https://doi.org/10.1002/cncr.22588
  7. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPVassociated head and neck squamous cell carcinoma. Cancer Research. 2013;73(6):1733-41. https://doi.org/10.1158/0008-5472.CAN-12-2384
  8. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141-51. https://doi.org/10.1016/S1074-7613(00)80089-8
  9. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682-7. https://doi.org/10.1038/nature04444 Ramsay AG. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. British Journal of Haematology. 2013;162(3):313-25. https://doi.org/10.1111/bjh.12380
  10. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology. 2001;2(3):261-8. https://doi.org/10.1038/85330
  11. Steidl C, Shah SP, Woolcock BW, et al. MHC class II